Pimavanserin: all 43 studies that test it

Page 1 of 1. Open to participants first (9), then studies with results posted, then the rest; newest registration first within each.

• Psilocybin Efficacy With or Without Pimavanserin PretreatmentRecruitingNCT07610135Phase 1/2
• Investigating the Neuropsychological Effects of 5-HT2a AntagonismRecruitingNCT07022366Not applicable
• Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive DisorderRecruitingNCT06592833Phase 2
• Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum DisorderRecruitingNCT05999240Phase 2
• Pimavanserin and Aggression and Social Cognition.RecruitingNCT05895513Phase 2
• Comparing Antipsychotic Medications in LBD Over TimeRecruitingNCT05590637Phase 4
• Pimavanserin for Insomnia in Veterans With PTSDRecruitingNCT05441280Phase 2
• Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative DiseasesRecruitingNCT05357612Phase 4
• Pimavanserin vs. Quetiapine for Treatment of Parkinson's PsychosisRecruitingNCT04373317Phase 4
• Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum DisorderTerminatedNCT05555615Phase 2/3Results posted
• Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum DisorderCompletedNCT05523895Phase 2/3Results posted
• Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of SchizophreniaCompletedNCT04531982Phase 3Results posted
• Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease PsychosisCompletedNCT04292223Phase 4Results posted
• Pimavanserin for Insomnia In Veterans With Posttraumatic Stress DisorderCompletedNCT04188392Phase 4Results posted
• Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose QuetiapineTerminatedNCT04164758Phase 2Results posted
• Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant TreatmentTerminatedNCT04000009Phase 3Results posted
• Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant TreatmentCompletedNCT03968159Phase 3Results posted
• Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative DiseaseCompletedNCT03623321Phase 3Results posted
• A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative DiseaseCompletedNCT03575052Phase 3Results posted
• Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and DepressionCompletedNCT03482882Phase 2Results posted
• Relapse Prevention Study of Pimavanserin in Dementia-related PsychosisCompletedNCT03325556Phase 3Results posted
• Extension Study of Pimavanserin for the Adjunctive Treatment of SchizophreniaTerminatedNCT03121586Phase 3Results posted
• A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's DiseaseCompletedNCT03118947Phase 2Results posted
• Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY)CompletedNCT03018340Phase 2Results posted
• Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (SERENE)TerminatedNCT02992132Phase 2Results posted
• Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE)CompletedNCT02970305Phase 2Results posted
• Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)CompletedNCT02970292Phase 3Results posted
• A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease PsychosisCompletedNCT02035553Phase 2Results posted
• An Open-label Safety Study of Pimavanserin in Parkinson's Disease PatientsCompletedNCT01518309Phase 2Results posted
• A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease PsychosisCompletedNCT01174004Phase 3Results posted
• A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease PsychosisCompletedNCT00658567Phase 3Results posted
• A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease PsychosisCompletedNCT00550238Phase 3Results posted
• A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease PsychosisCompletedNCT00477672Phase 3Results posted
• Bioequivalence Study of Pimavanserin 34 mg CapsuleCompletedNCT06450184Phase 1
• A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease PsychosisCompletedNCT06068465Phase 3
• Pimavanserin for Sleep in Parkinson DiseaseWithdrawnNCT05796167Early Phase 1
• Pimavanserin for Insomnia in Veterans With Posttraumatic Stress Disorder: Proof of ConceptWithdrawnNCT04809116Phase 4
• Pimavanserin Treatment in TSCompletedNCT04794413Early Phase 1
• The Sub-Sero StudyWithdrawnNCT03994965Phase 2
• Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.CompletedNCT03947216Phase 2
• Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol and RisperidoneCompletedNCT00361166Phase 2
• Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational DrugCompletedNCT00087542Phase 2
• ACP-103 to Treat Parkinson's DiseaseCompletedNCT00086294Phase 2

← Pimavanserin overview